IL15 and colorectal carcinoma: IL-15 enhances NK proliferation, survival, and IFN-γ production (Waldmann, 2003), with IL-15 super agonists (e.g., ALT-803) showing promising results in MSI-H CRC (Objective response rate-ORR 25%–35%, PFS 8–10 months) (Wrangle et al., 2018; Andr’e et al., 2020).